 The study compares the impact on quality of life, Coal, between achieving POSI 75 and POSI 90 in patients with moderate to severe plaque psoriasis treated with Adalimumab or Ostequinumab. Results show no statistically significant difference in psychological general well-being, PGWB, scores between the two groups, but a significant difference in dermatology life quality index, DLQI, at week 24 for the Adalimumab treatment group. No significant differences were found in PGWB or DLQI scores between the two groups in the Ostequinumab treatment group. The study suggests that while newer biologic agents can achieve POSI 90, there may not be a clinically significant difference in Coal when comparing patients who achieve POSI 75 versus POSI 90. This article was authored by Michael Abruke, M. Nokomura, THU, and others.